These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 19122266)

  • 41. Corticosteroids: no drug prevention of fractures needed.
    Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
    Voskaridou E; Christoulas D; Antoniadou L; Terpos E
    Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
    [No Abstract]   [Full Text] [Related]  

  • 43. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143
    [No Abstract]   [Full Text] [Related]  

  • 44. How effective is bisphosphonate treatment for preventing bone fractures after liver transplantation?
    Hay JE
    Nat Clin Pract Gastroenterol Hepatol; 2008 Apr; 5(4):190-1. PubMed ID: 18268522
    [No Abstract]   [Full Text] [Related]  

  • 45. Minodronate for the treatment of osteoporosis.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
    Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Bone metabolic marker for osteoporosis].
    Shidara K; Inaba M
    Nihon Rinsho; 2009 May; 67(5):927-31. PubMed ID: 19432111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bone quality].
    Ito M
    Nihon Rinsho; 2009 May; 67(5):921-5. PubMed ID: 19432110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment goals of osteoporosis].
    Hosoi T
    Clin Calcium; 2014 Mar; 24(3):385-9. PubMed ID: 24576935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical use of serum and urine bone markers in the management of osteoporosis.
    Srivastava AK; Vliet EL; Lewiecki EM; Maricic M; Abdelmalek A; Gluck O; Baylink DJ
    Curr Med Res Opin; 2005 Jul; 21(7):1015-26. PubMed ID: 16004668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of osteoporosis medications on bone quality.
    Benhamou CL
    Joint Bone Spine; 2007 Jan; 74(1):39-47. PubMed ID: 17196423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.
    Armamento-Villareal R; Napoli N; Diemer K; Watkins M; Civitelli R; Teitelbaum S; Novack D
    Calcif Tissue Int; 2009 Jul; 85(1):37-44. PubMed ID: 19548019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
    Hosoi T
    Clin Calcium; 2009 Jan; 19(1):11-8. PubMed ID: 19122260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Osteoporosis in patients with diabetes mellitus].
    Yamauchi M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():526-30. PubMed ID: 18161160
    [No Abstract]   [Full Text] [Related]  

  • 56. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
    Brufsky AM
    Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What is new in the treatment of steroid-induced osteoporosis?
    Liu RH; Werth VP
    Semin Cutan Med Surg; 2007 Dec; 26(4):203-9. PubMed ID: 18395668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Bisphosphontes].
    Ichimura S
    Clin Calcium; 2005 Apr; 15(4):583-90. PubMed ID: 15802769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Bisphosphonate].
    Hagino H
    Nihon Rinsho; 2011 Jul; 69(7):1253-7. PubMed ID: 21774367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do not use bisphosphonate therapy indefinitely for fracture prevention.
    Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.